News

   

Oncoinvent ASA: Second half 2025 results

Oslo, Norway, 26 February 2026: Oncoinvent (OSE: ONCIN), a biotech…

Link Biologics strengthens Board with drug discovery expert Dr Niall Martin to advance its TSG-6-based therapeutic pipeline

Dr Martin brings over two decades of leadership in translational…

Hansa Biopharma presenting at TD Cowen’s 46th Annual Health Care Conference

Lund, Sweden, 23 February, 2026. Hansa Biopharma AB, “Hansa”…

Biocomposites to launch SYNICEM bone cement in UK to ease supply crisis

• Biocomposites responds to NHS supply crisis by bringing…

Philanthropic Partnership Backs Country-Led Research to Guide the Use of AI in Health

The Novo Nordisk Foundation, Gates Foundation, and Wellcome will…

Hansa Biopharma’s Biologics License Application (BLA) for imlifidase accepted by the FDA

Lund, Sweden, 18 February 2026. Hansa Biopharma AB, (“Hansa”…

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin® at ESGO 2026

9 of 10 patients at the highest dose remained free from peritoneal…

Nucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer

Brings deep expertise in immunology, oncology and pharmacology…

Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026

Oslo, Norway, 16 February 2026: Oncoinvent ASA (ONCIN), a biotech…

AmacaThera Named Life Sciences Ontario Emerging Company of the Year

Recognition of AmacaThera’s leadership and landmark agreement…

Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results

· Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024. ·…

Hans Schambye Appointed as Chief Executive Officer of BOOST Pharma

Advancing development of lead candidate BT-101, a potential…

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Financing led by Investissement Québec with continued support…

Biocomposites gains MDR certification for STIMULAN® Rapid Cure and STIMULAN® Kit

STIMULAN® certified to be mixed with a combination of Gram-positive…

Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial

Oslo, Norway, 29 January 2026: Oncoinvent, a clinical stage,…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.